How EBC-46 Destroys Tumours: The PKC-δ Signalling Pathway Explained
Among the compounds emerging from rainforest-derived pharmacognosy research, tigilanol tiglate (EBC-46) stands out for its unusually rapid and localised antitumour effect. Within hours of direct intratumoural injection, observable tumour destruction occurs — a timeline that differs markedly from conventional chemotherapy. Understanding why requires examining the compound's interaction with the protein kinase C (PKC) superfamily, particularly the delta isoform.
Protein Kinase C: A Family of Cellular Switches
PKC enzymes are serine/threonine kinases that regulate a wide range of cellular processes: proliferation, differentiation, apoptosis, and cytoskeletal reorganisation. The PKC family comprises at least 10 isoforms grouped into classical (α, β, γ), novel (δ, ε, η, θ), and atypical (ζ, ι/λ) subfamilies based on their activation requirements. Novel PKC isoforms, including PKC-δ, are activated by diacylglycerol (DAG) but do not require calcium.
Tigilanol tiglate is a tigliane-type diterpene ester that acts as a potent, selective activator of PKC isoforms — principally PKC-δ within tumour-associated vascular tissue. Its structural similarity to phorbol esters allows it to compete for the DAG binding site on PKC's C1 domain, producing sustained kinase activation.
Vascular Disruption as the Primary Mechanism
Preclinical research by Boyle et al. (2014) demonstrated that EBC-46 exerts its primary cytotoxic effect through vascular disruption within the tumour microenvironment. PKC-δ activation in endothelial cells triggers cytoskeletal changes — specifically, actin stress fibre formation and VE-cadherin internalisation — that rapidly compromise the structural integrity of tumour blood vessels.
The result is haemorrhagic necrosis: blood flow to the tumour is cut off, causing ischaemic death of cancer cells. This mechanism is distinct from direct apoptosis induction and explains the characteristic "eschar" formation observed in both preclinical models and human trials within 24–72 hours post-injection.
Immune System Activation: Beyond Simple Necrosis
A second important mechanism involves the immunogenic quality of EBC-46-induced cell death. Unlike some forms of necrosis that are immunologically silent, tigilanol tiglate-mediated tumour destruction releases damage-associated molecular patterns (DAMPs) — including calreticulin, HMGB1, and ATP — that signal to dendritic cells and initiate an adaptive immune response.
Post-treatment histology in canine mast cell tumour studies showed significant CD8+ T-cell infiltration at the treatment site within 7 days, suggesting that the compound promotes a degree of "immune priming" that may contribute to durable responses observed in some animals even at distant sites.
Why Oral Supplementation Is Mechanistically Uncertain
Understanding this mechanism clarifies why extrapolating from injectable pharmaceutical EBC-46 to oral blushwood berry supplements is scientifically problematic. The vascular disruption mechanism requires the compound to reach tumour endothelial cells at sufficient concentration — something achieved reliably by direct injection but not yet demonstrated for orally administered extract. Tigliane diterpene esters are susceptible to hydrolysis in the gastrointestinal environment, and no published pharmacokinetic study has characterised oral bioavailability of tigilanol tiglate in humans.
Implications for Supplement Research
The precise mechanism of action does highlight potential value in continued research into oral formulations — particularly if delivery systems capable of protecting tigilanol tiglate from gastric degradation (liposomal or nanoparticle encapsulation, for example) can be validated. Several preclinical groups are reportedly investigating this avenue, though no results have been peer-reviewed as of early 2026.
Citations
1. Boyle GM, et al. "Intratumoural injection of the novel PKC activator EBC-46 rapidly ablates tumours in mouse models." PLOS ONE, 2014; 9(10): e108887.
2. Reddell P, et al. "First in Human Phase 1 Clinical Trial of EBC-46 by Intra-Tumoral Injection." Cancers, 2020; 12(11):3365.
3. Nakashima S. "Protein Kinase Cδ (PKC δ) and its functions." Journal of Biochemistry, 2002; 132(5):669–675.
